Equity Raising Presentation
Released
Released
Announcement PDF
Commercialising a
New Class of Synthetic
Anti-Infectives
RECCE PHARMACEUTICALS LIMITED
|
EQUITY RAISING PRESENTATION
APRIL 2025
|
(ASX:RCE)(FSE:R9Q)
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
1
Important Notice and Disclaimer
Disclaimer
This presentation is dated 10 April 2025 and has been prepared by Recce Pharmaceuticals Limited (ACN 124 849 065) (Recce or the Company) in connection with a placement and entitlement offer of new fully
paid ordinary shares (New Shares) in the Company (the Offer). By receiving this presentation, you are agreeing to the following restrictions and limitations.
Summary Information
This presentation contains summary information about Recce and its subsidiaries, and their activities current as at the date of the presentation. The information in this presentation is general in nature and does
not purport to be complete, nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Recce. The historical information in this presentation is, or is
based upon, information that has been released to the ASX. This presentation should be read in conjunction with Recce’s other periodic and continuous disclosure announcements lodged with ASX, which are
available at www.asx.com.au. The information contained in this presentation is provided as at the date of this presentation (unless otherwise stated) and is subject to change without notice. Recce is not obligated
to update it or correct it.
Not An Offer
This presentation is for information purposes only and is not a prospectus, product disclosure statement or other disclosure or offer document under Australian law or under any other law. It will not be lodged
with the Australian Securities and Investments Commission (“ASIC”) or any other local or foreign regulator or law. This presentation is not an offer or an invitation to acquire the New Shares or any other financial
products in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer or invitation. The New Shares will only be offered or issued in Australia to investors to whom offers and
issues of New Shares may lawfully be made in Australia without the need for disclosure to investors under Chapter 6D of the Corporations Act 2001 (Cth). The distribution of this presentation and the offer of New
Shares is restricted in jurisdictions outside Australia. You should read the restrictions set out in the section of this presentation headed “International Selling Restrictions” for more information. Any failure to
comply with such restrictions may constitute a violation of applicable securities laws. By accepting this presentation, you represent and warrant that you are entitled to receive this presentation in accordance
with those restrictions and agree to be bound by them and any other limitations contained in this presentation.
In particular, this presentation may not be released to US wire services or distributed in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in
the United States or any other jurisdiction in which such an offer would be illegal. The New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities
Act”), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to,
the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
2
Important Notice and Disclaimer
Not Financial Product Advice
This presentation does not, and does not purport to, contain all the information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) or
any recommendation to acquire New Shares, and must not be relied upon as such and does not and will not form any part of any contract or commitment for the acquisition of New Shares. Any decision to buy or
sell securities or other products should be made only after seeking appropriate financial advice. This presentation is of a general nature and does not take into consideration the individual investment objectives,
financial situation or particular needs of any particular investor. Before making any investment decision, you should consider the appropriateness of the information having regard to your own objectives, financial
situation and particular needs, and seek appropriate professional advice from your stockbroker, solicitor, accountant or other independent and qualified professional adviser. Each recipient of this presentation
should make their own enquiries and investigations regarding all information included in it, including the assumptions, uncertainties and contingencies which may affect Recce’s future operations, and the impact
that future outcomes may have on Recce and its controlled entities (the “Group”). For more information about Recce, visit the website at www.recce.com.au.
Investment Risk
An investment in Recce is subject to both known and unknown risks, some of which are beyond the control of Recce and its directors. Recce does not guarantee any particular rate of return or the performance of
Recce nor does it guarantee any particular tax treatment. You should have regard to the risk factors outlined in the section of this presentation headed “Key Risks” when making your investment decision. Cooling
off rights do not apply to the acquisition of New Shares.
Financial Data
Unless otherwise stated, or as the context requires, all figures in this presentation are in Australian dollars. Certain financial information and measures included in this presentation are (i) “non-IFRS financial
information” under ASIC Regulatory Guide 230: “Disclosing non-IFRS financial information” and (ii) “non-GAAP financial measures” under Regulation G issued by the U.S. Securities and Exchange Commission
(“SEC”) and are not recognised under Australian Accounting Standards (“AAS”) and International Financial Reporting Standards (“IFRS”). Therefore, the non-IFRS/non-GAAP financial information may not be
comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Recce believes these
non-IFRS/non-GAAP financial measures provide useful information to investors in measuring the financial performance and condition of its business. However, investors should note that the non-IFRS/non-GAAP
financial measures do not have standardised meanings prescribed by AAS or IFRS. Investors are therefore cautioned to not place undue reliance on any non-IFRS/non- GAAP financial information included in this
presentation.
This presentation includes certain pro forma financial information (to reflect the impact of the equity raising). The pro forma historical financial information provided in this presentation is for illustrative purposes
only and is not represented as being indicative of Recce’s views on its future financial position and/or performance. The pro forma historical financial information has been prepared by Recce in accordance with
the measurement and recognition principles, but not the disclosure requirements, prescribed by the AAS. In addition, the pro forma financial information in this presentation does not purport to be in compliance
with Article 11 of Regulation S-X of the rules and regulations of SEC. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of
rounding. Accordingly, the precise calculation of these figures may differ from the figures set out in this presentation.
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
3
Important Notice and Disclaimer
Past Performance
No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum
extent permitted by law, none of Recce or its directors, or any of their employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for
any loss arising from the use of the information contained in this presentation. In particular, no representation or warranty, express or implied is given as to the accuracy, completeness or correctness, likelihood
of achievement or reasonableness of any forecasts, projections, prospects or returns contained in this presentation, nor is any obligation assumed to update such information. Such forecasts, prospects or
returns are by their nature subject to significant uncertainties and contingencies.
Past performance and pro forma historical financial information is given for illustrative purposes only. It should not be relied on and is not an indication of future performance, including future share prices. For
further details on historical information relating to the Group, you should see past announcements that Recce has released to ASX.
Market Data
Certain market and industry data used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Recce nor its
representatives or its advisers have independently verified any such market or industry data provided by third parties or industry or general publications.
Future Performance and Forward-Looking Statements
This presentation contains certain “forward-looking statements”. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”,
“estimate”, “anticipate”, “believe”, “continue”, “should”, “could”, “predict”, “objectives”, “outlook”, “guidance” or other similar words, statements regarding certain plans, strategies and objectives of
management, indications of and guidance or outlook on production estimates and targets, statements about current and future plans regarding exploration, statements about the outcome and effect of the
proposed Placement, statements about other opportunities, and expected future earnings and financial earnings and performance.
Forward looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks,
uncertainties and other factors, which are outside the control of Recce and any of its officers, employees, agents or associates. This also includes statements about market and industry trends, which are based
on interpretations of current market conditions. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those
statements are based. Forward-looking statements may be affected by a range of variables, including but not limited to the risks described in this presentation under the section headed "Key Risks". Investors are
strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility and uncertainty. Forward-looking statements are
provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.
These statements may assume the success of Recce’s business strategies, the success of which may not be realised within the period for which the forward-looking statement may have been prepared, or at all.
No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Recce, its representatives or advisers undertakes any obligation to provide any additional or
updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial
position or performance are also forward-looking statements.
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
4
Executive Summary
Commercialising a new class of synthetic anti-infectives
Overview of Recce
Pharmaceuticals
• Recce Pharmaceuticals Limited (Recce or the Company) is developing a New Class of Synthetic Anti-Infectives with the potential to overcome antibioticresistant superbugs – the challenge of all antibiotics to date
• Lead drug candidate RECCE® 327 is recognized by the World Health Organization as one of the world’s most clinically advanced new classes of antibiotics - the
first in over 40 years
• Recce has a strong pipeline of Phase II / III clinical trials across multiple key geographies with significant revenue catalysts over the next 12 months
Key milestones over the
next 12 months
• Registrational Phase III clinical trial of R327 topical gel in Indonesia - the catalyst for revenues in CY2026
• Successful ABSSSI Phase II R327 topical gel clinical trial progressing to a Registrational Phase III clinical trial in Australia on-track to launch mid-year
• USA Department of Defense Burns Grant of US$2.2 million (~A$3.3 million) facilitating late-stage pre-clinical data
Registrational Phase III
trial catalyst for revenue
in 2026
• Memorandum of Understanding (MoU) with leading biomedical company PT Etana Biotechnologies (Etana) to facilitate late-stage clinical trials in Indonesia,
supporting the Indonesian Government’s access to novel infectious disease medicines
• Approval received from the Indonesian Drug and Food Regulatory Authority, Badan POM, to initiate Registrational Phase III clinical trial
• Awarded expedited regulatory review status in Indonesia to fast-track progression of Phase III trial; brings forward commercial opportunities in ASEAN region
• Opportunity to access 10 ASEAN member states covering a population of 680 million inhabitants as well as other geographic regions
• Significant bilateral initiative supported by Australian and Indonesian Governments
Capital raising to
advance Phase III trials
and commercialisation
• A$5.0 million placement and up to ~A$10.8 million 1-for-6 non-renounceable entitlement offer to raise up to a total of ~A$15.8 million (the Offer)
• Funds raised under the Offer will fund significant clinical trials for topical treatments in Indonesia which will progress Recce through to commercialisation,
Phase III trials in Australia, continued development of pre-clinical portfolio, Investigational New Drug Application to the FDA and working capital
• Offer price of A$0.28 per new share (Offer Price), which represents a:
o 13.8% discount to the last traded price (A$0.325) on 9 April 2025
o 19.8% discount to the 10-day VWAP (A$0.3492) as at 9 April 2025
o 11.4% to the theoretical ex-rights price (TERP) of A$0.3162 per share as at 9 April 2025 (assuming full take-up under the Entitlement Offer)
• Post completion, Recce will have available funding of up to ~$17.7 million*.
*Includes cash balance as at 31 December 2024 of A$1.9 million plus Offer Proceeds (before Offer costs), assuming full take-up under the Entitlement Offer.
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
5
Company
Overview
6
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
6
Leading, Australian Anti-Infective Company
Near-term commercialisation pathway expected to launch in 2026
Products address the global healthcare crisis of antibiotic resistance
Phase III in Indonesia of lead asset RECCE® 327 Gel for the treatment of
Diabetic Foot Infections – Expected launch in 2026 and opens gateway to
ASEAN and other markets
Multiple clinical indications and formulations in Phase I and II addressing
unmet medical needs
US FDA Qualified Infectious Disease Product designation provides 10
years of market exclusivity plus fast-track approval*
World Health Organization added RECCE® compounds to its list of
antibacterial products in clinical development for priority pathogens
*Awarded by the US FDA in 2017 for R327 bacteraemia (broad-spectrum bacterial sepsis). Time starts only from potential market approval
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
7
Synthetic Anti-Infectives
The need for a new class of antibiotics
On-track to be the only global clinical stage company whose drug is
shown to be efficacious against the full suite of ESKAPE pathogens
NO pre-formed natural
superbugs
Very broad-spectrum coverage
of bacteria with no signs of
resistance
Universal Mechanism of Action
- does not succumb to
resistance
Unprecedented, broadspectrum activity against Gram
+ve and Gram -ve bacteria
and maintains its activity even
with repeated use
Extremely rapid onset of effect
– measured in minutes as
compared to hours for typical
antibiotics
Multiple formulations available
– intravenous, topical liquid,
topical gel and aerosol for
inhalation or intranasal
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
8
Large Addressable Market
The global diabetic foot infection (DFI) and sepsis market is worth over $US9.1 billion
US$5.2B
Est. global DFI
treatment
market1
•
The DFI treatment market is estimated to be worth ~US$5.2 billion1
•
Initially targeting Indonesian market valued at ~US$189 million where
DFI impacts 11% of the population2
•
Significant near-term opportunity for Recce with registrational Phase
III trials anticipated to be completed in FY26 paving the way for future
revenues
•
Indonesian approvals provide access to the broader Asia Pacific
market worth ~US$1.0 billion per year3
•
The global sepsis therapeutics market size is anticipated to reach
US$5.64 billion by 2030, growing at a CAGR of 6.18% from 2025 to
20304
•
Recce is initially targeting US and Australian markets worth in excess
of US$1.5 billion4
US$3.9B
Est. global
sepsis market4
~US$135.4B
Estimated value of the
significant additional market
opportunities in the broader
anti-infectives market
Recce already exploring
opportunities in burn wound
infections, skin and soft
tissue infections post
operation5
Source: (1) Grand View Research, Diabetic Foot Ulcer Treatment Market Size, 2023 (2) Diabetes Atlas, International Diabetic Federation and Prof EM Yunir, Faculty of Medicines, University of Indonesia.
(3) Business Market Insights, Asia Pacific Diabetic Foot Ulcer Market, 2021 (4) ResearchandMarkets, Global Sepsis Therapeutics, 2024 (5) Grand View Research, Anti-Infective Agents Market Size, 2023
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
9
Program Pipeline for 2025
Various indications and upcoming inflection points
Program
Indications
Diabetic Foot Infections
Indonesia (ASEAN)
R327 Topical Gel
Registrational Trials
Pre-clinical
Phase I
Phase II
Phase III
Market
•
Approval received from
the Indonesian Drug and
Food Regulation Authority,
Badan POM, to initiate its
Registrational Phase III
clinical trial in Indonesia
•
ABSSSI includes
postoperative infection,
wound infections and
diabetic foot infections
•
Completed pilot civil
Phase II Burn Wound
Infections Study; US$2M
grant for Department of
Defense pre-clinical
pipeline in progress
Phase III starts H1 2025
Diabetic Foot Infections
Australia
Diabetic Foot Infections
USA – IND
R327 Topical Gel
Discovery
Acute Bacterial Skin and Skin
Structure Infections (ABSSSI)
Australia
R327 Intravenous
and Backups
cUTI/Hospital and Ventilator
Acquired Pneumonia
Other Serious Infections
Aerosol for
Inhalation
Hospital-acquired Pneumonia
Ventilator-associated Pneumonia
Serious Lung Infections
Civil and Dept of
Defense Programs
Burn Wound Infections
IND Late 2025/Early 2026
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
10
Multiple Clinical Milestones – Achieved and Upcoming
Significant milestones anticipated in 2025
Pre FY2025
Phase I/II Clinical Trial for the Treatment
of Burn Wound Infections Phase I
complete
R327G indicated positive clinical
response in the treatment of multiple
antibiotic-resistant infections under TGA
Special Access Scheme Category A
R327 Phase I/II UTI/Urosepsis Rapid
Infusion Clinical Trial - safe and well
tolerated at faster infusion rates ~30min
for 2,500mg and 3,000mg
MoU with PT Etana Biotechnologies
Indonesia to work collaboratively on R&D,
production, distribution and
commercialisation of R327
Previous 12 Months
Phase II Acute Bacterial Skin and Skin
Structure Infections (ABSSSI) including
Diabetic Foot Infections (DFI) clinical trial
complete, meeting all endpoints
US Department of Defense grants US$2.0
million funding to accelerate
development of R327 for acute treatment
of burn wound infections
Regulatory and ethics approval received
for Indonesian Registrational Phase III
trial in Diabetic Foot Infections
2025 and 2026
Launch Registrational Phase III trial for
DFI in Indonesia
Launch Registrational Phase III trial for
ABSSSI in Australia
Commencement of US Department of
Defense Burn Wound Program
File Investigational New Drug Application
for R327 in the USA
Launch Phase II UTI/Urosepsis Clinical
Trial (with data readouts throughout)
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
11
Commercialisation Pathway in DFI and ABSSSI:
Positive Phase II and SAS data → Start Phase III in DFI
DFI & ABSSSI
Clinical
Programs
Phase II
Data 2H24
Indonesia:
DFI Phase III Clinical Trial
NDA
Submission
Australia & US:
ABSSSI/DFI Phase III Clinical Trial
NDA
Submission
US: IND & Clinical Trials
2024
2025
2026
2027
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
12
Experienced Board of Directors
Dr John Prendergast – Chairman
Michele Dilizia – Executive Director & Chief Scientific Officer
US-based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE:
PTN) and Lead Director of Nighthawk Biosciences (NYSE: HHWK). With extensive
experience in the international commercialisation of pharmaceutical technologies,
Dr Prendergast has been responsible for the approval of three new drug applications.
Co-inventor and qualified medical scientist with a specialisation in medical
microbiology and regulatory affairs. Ms Dilizia successfully co-led the research and
development of Recce’s suite of anti- infective compounds, resulting in a portfolio of
granted patents across the globe, including a Qualified Infectious Disease Product
designation with the U.S. FDA.
James Graham – Managing Director & Chief Executive Officer
Dr Justin Ward – Executive Director & Principal Quality Chemist
Six years as former Executive Director and extensive experience in marketing,
business development and commercialisation of early-stage technologies with
global potential. Mr Graham has served on Recce’s Board of Directors for six years
with a focus on expanding Recce’s commercial opportunities and clinical initiatives.
A quality control expert who has worked with leading pharmaceutical companies.
He previously held a technical role with Pfizer, involving providing data for the
regulatory submissions to the FDA and TGA. Dr Ward is bringing Recce’s research
and development and manufacturing up to US FDA requirements.
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)
BCom (Entrepreneurship), GAICD
BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM
BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem
Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director
BSc (BioChem) Hons, M.D. (NYU)
US based, Director of Palatin Technologies. Over three decades of senior
pharmaceutical experience incl. President and MD of Janssen Research
Foundation (Johnson & Johnson). Advanced several blockbuster antibiotics
through regulatory review and commercialisation at Fortune 500 companies
including Roche. Responsible for the approval of approximately 20 New Drug
Applications; an amalgamation of prescription and OTC products.
Alistair McKeough – Non-Executive Director
Alistair is a qualified lawyer and specialises in complex commercial matters that
require careful and strategic planning. Mr McKeough has extensive experience
advising ASX-listed companies and their directors.
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
13
Company Overview: Recce Pharmaceuticals Ltd
A clinical-stage Australian biotech company with a new class of synthetic anti-infectives
Capital Structure – March 2025
Share Price & Volume – March 2025
ASX & FSE Code
RCE, R9Q
$0.80
3,000,000
Share Price
AUD $0.37
$0.70
2,500,000
$0.60
2,000,000
$0.50
1,500,000
$0.40
1,000,000
$0.30
500,000
3-Month Average Daily Volume
Shares on Issue
Unlisted Options (Avg $1.54)
115.49k
231.87 million
13.9 million
Market Capitalisation
AUD $84.6 million
Cash at Bank*
AUD $1.94 million
Top 20 Shareholders
50%
Debt
Nil
Proprietary first-in-class,
broad-spectrum anti-infectives
against bacteria
Australian Government awarded AUD
$54,947,284 (USD $37,043,433) with
Advanced Overseas Finding across RCE
infectious disease portfolio**
$0.20
Mar 2024
Apr 2024 May 2024
Jun 2024
Jul 2024
Aug 2024
Sep 2024 Oct 2024
Volume
Close $
I.V. and topical treatments advancing for
UTI/Urosepsis and Acute Bacterial Skin and Skin
Structure Infections (ABSSSI) including DFI; as well as
US Department of Defense Burn Wound Program and
Indonesian clinical trials for topical treatments.
Nov 2024 Dec 2024
Jan 2025
Feb 2025
0
Multiple clinical indications and formulations
in Phase I and Phase II addressing unmet
medical needs: Sepsis, UTI/Urosepsis, Burn
Wounds and ABSSSI, including Diabetic
Foot Infections
*Cash balance does not reflect Q3, 2024 announced U.S. Department of Defense Army burn wound grant of US$2.0 million (~A$3 million) or anticipated additional R&D advance funds.
**The Advanced Finding is a binding, underwritten guarantee provided by the Australian Government, which affirms the Company’s R&D activities are of national interest and extends the 43.5% R&D rebate from locally, to cover those
undertaken by the Company anywhere in the world for a period of three years. This finding does not constitute a grant, or an upfront payment of the amount awarded
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
14
R327 Solution
15
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
15
Independent Study Undertaken on RECCE® 327 MoA1
Linnaeus Biosciences MoA studies of R327
Recce products work via a NOVEL MECHANISM which targets rapid access to and shut down of bacterial
energy production (ATP), which results in bacterial death of both active and resting bacteria
Stage 1
Stage 2
Stage 3
Stage 4
R327 targets and irreversibly
bind to essential bacterial
proteins
R327 interferes with bacterial
cellular metabolism and
energy production at or near
the cell surface, depleting ATP
R327 kills bacteria rapidly
without inducing cell lysis
R327 is rapidly and
irreversibly bactericidal
Note (1): Dilizia, M., Tsunemoto, H., Quach, D. et al. Elucidating the Mechanism of Action of Novel Polymer-based Synthetic Anti-infective Compound RECCE 327 - Abstract
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
16
R327 Faster Acting Than Existing Antibiotics
No prolonged exposure needed
R327 is faster-acting against bacteria than other antibiotics – works quickly, without prolonged cellular
exposure times required of other antibiotics (extended exposures commonly associated with systemic toxicity)
R327 shuts down ATP
production, the driver of
bacterial energy irreversibly
in minutes
Because of its unique MoA,
R327 kills pathogenic
bacteria at a faster rate
than any known antibiotic
and it is the only clinical
candidate currently being
developed to target ATP
disruption
R327 kills bacteria in conditions where
other antibiotics are ineffective
- Marc Sharp, PhD, Chief Scientific Officer, Linnaeus Bioscience
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
17
RECCE® 327 – Global Recognition
R327 added to WHO’s list of antibacterial products in clinical development
Number of compounds by antibiotic class
Cell wall inhibitors
15
Cell membrane disruptors
6
Protein synthesis inhibitors
4
NBTIs
3
Fabl inhibitors
1
FtsZ inhibitors
1
ATP production disruptors
1
Antibiotic hybrids
1
RECCE®327 (R327)
Global recognition by the World Health
Organization (WHO): Inclusion underscores
significance of R327 in combating antimicrobial
resistance
Unique Mechanism of Action: R327 uniquely
classified as an adenosine triphosphate (ATP)
production disruptor, the only compound under
this category
R327 recognised as a novel treatment: For a broad
range of life-threatening and resistant bacteria
The WHO report covers traditional and non-traditional antibacterial agents in development worldwide and evaluates
to what extent the present pipeline addresses infections caused by priority pathogens
Recce Pharmaceuticals Limited (ASX:RCE)
|
Equity Raising Presentation |
18
RECCE® 327 – NO RESISTANCE on Serial Passaging
Amoxicillin loses activity after a maximum of 8 repeats; RECCE® 327 remains active for more than 25 repeats
25 repeats at time of discovery was sufficient for PCT patent applications, with no sign of resistance
Number of repeats before displaying loss of antibiotic activity
2
4
6
8
10
12
14
16
18
20
22
24
Share your feedback
Discover